AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 132 min read$AKTX

Akari Therapeutics Plc (AKTX): Results of Operations and Financial Condition

Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001541157 0001541157 2026-08-13 2026-08-13 0001541157 AKTX:AmericanDepositarySharesEachRepresenting80000OrdinarySharesMember 2026-08-13 2026-08-13 0001541157 AKTX:OrdinarySharesParValue0.000000005PerShareMember 2026-08-13 2026-08-13 iso4217:USD xbrli:shares iso4217:USD xbr

Original reporting
SEC EDGAR 8-K
Published Aug 13, 2026, 8:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$AKTX
Neutral
low confidence
Mentioned
$AKTX
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AKTXNeutralLow
01

Why it matters

Interim financial-result disclosures can affect valuation via revenue trajectory, burn rate, and liquidity. However, the provided text does not include the underlying financial figures or any forward-looking statements.

02

Market read

This excerpt is a filing mechanics disclosure that interim results were issued, but it lacks the specific numbers needed to forecast trading impact.

03

What to watch

Traders should verify Exhibit 99.1 for cash runway, operating expense changes, and any updated development milestones, which can drive outsized reactions even when the 8-K cover text looks routine.

Relevance 7/10Novelty 3/10Timing: filed Aug 13, 2026 after market hours

Background

The company furnished an 8-K under Item 2.02, stating it issued a press release with first-half 2026 financial results and other information, filed as Exhibit 99.1.

Company-level read

Ticker impact

$AKTXNeutralLow confidence
Context

Akari Therapeutics filed an 8-K furnishing its first-half 2026 financial results press release under Item 2.02.

Expected impact

Likely modest, unless the attached Exhibit 99.1 contains material beats/misses or liquidity updates not shown here.

Evidence & confidence

The filing confirms the company issued a results press release, but the provided body contains no performance metrics, cash balance, or outlook details to assess magnitude.

Market effects

Sector

Limited signal for the broader biotech sector because no clinical, regulatory, or product-specific details are included in the scraped text.

Regional

No clear regional spillover indicated by the filing excerpt.

Global

No global macro or cross-border transaction details provided beyond the company’s interim reporting.

Counterpoint

What could challenge this read

The market may already be positioned for interim results; without the Exhibit 99.1 figures, the incremental trading edge from this excerpt is small.

Key entities

  • issuer
    Akari Therapeutics, Plc

    Nasdaq-listed company (AKTX) that furnished its interim financial results press release via an 8-K.

  • filing_exhibit
    Exhibit 99.1

    Press release dated Aug 13, 2026 containing the actual financial results referenced by Item 2.02.

  • SEC_filing_item
    Item 2.02

    Section of the 8-K covering results of operations and financial condition.

Read at source← All news

Related articles

MAY 30
$AKTXMed

Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics (NASDAQ:AKTX) saw short interest rise to 64,685 shares as of May 15, up from 16,135 on April 30, with about 8.2% of shares sold short and a short-interest ratio of 1.8 days. Armistice Capital bought 2,723,966 shares in Q4, valuing the stake at ~$787,000 (5.95%). Analysts’ consensus is “Hold” with a $89 target. The stock traded at $16.43; EPS missed on May 20.

dailypolitical.com4 min
MAY 29
$SPRCMedAI 8/10

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

rttnews.com6 min
AUG 13
$ALMSMed

ALUMIS INC. (ALMS): Results of Operations and Financial Condition

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alms-20260813xex99d1.htm EX-99.1 ​ Exhibit 99.1 ​ ​ Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements ​ – ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new stand

SEC EDGAR 8-K6 min
AUG 13
$MFPHigh

Midera Food Processing, Inc. (MFP): Results of Operations and Financial Condition

Midera Food Processing, Inc. (MFP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0002088281-ex99_1.htm EX-99.1 EX-99.1 MIDERA FOOD PROCESSING REPORTS SECOND QUARTER 2026 RESULTS IN FIRST REPORT AS AN INDEPENDENT PUBLIC COMPANY Completed separation from The Middleby Corporation on July 6, 2026 Strong demand with orders up 16% year-over-year Raises

SEC EDGAR 8-K6 min
AUG 13
$TSSIMed

TSS, Inc. (TSSI): Results of Operations and Financial Condition

TSS, Inc. (TSSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tssi_ex991.htm PRESS RELEASE tssi_ex991.htm EXHIBIT 99.1 TSS Reports Second Quarter 2026 Financial Results Systems Integration Revenue Increased 46% Year-Over-Year, Representing 39% of Total Revenue ~$17 Million Investment Expected to Drive Increased Systems Integration

SEC EDGAR 8-K6 min
AUG 13
$CVMed

CapsoVision, Inc (CV): Results of Operations and Financial Condition

CapsoVision, Inc (CV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 2 cv-20260813xex101.htm EX-10.1 Document Exhibit 10.1 CapsoVision, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity Offering SM Sales Agreement August 13, 2026 Cantor Fitzgerald & Co. 110 East 59 th Street New York, NY 10022 Ladies and Gentlemen:

SEC EDGAR 8-K3 min